

Frequencies

[DataSet10]

Statistics

		basal insulin	prandial insulin	SGLT2i	GLP-1RA	DPP-4i	Combinations
N	Valid	32	32	32	32	0	0
	Missing	0	0	0	0	32	32

Statistics

		patient gender	patient insurance type	metformin use	sulfonylurea use	meglitinide use
N	Valid	32	32	32	32	32
	Missing	0	0	0	0	0

Statistics

		TZD use	other insulin use
N	Valid	32	32
	Missing	0	0

Frequency Table

basal insulin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid		13	40.6	40.6	40.6
	Basaglar	11	34.4	34.4	75.0
	Tresiba	8	25.0	25.0	100.0
	Total	32	100.0	100.0	

prandial insulin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid		26	81.3	81.3	81.3
	Humalog	2	6.3	6.3	87.5
	Novolog	4	12.5	12.5	100.0
	Total	32	100.0	100.0	

SGLT2i

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid		21	65.6	65.6	65.6
	Farxiga	6	18.8	18.8	84.4
	Jardiance	4	12.5	12.5	96.9
	non-PAP SGLT2	1	3.1	3.1	100.0
	Total	32	100.0	100.0	

GLP-1RA

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid		6	18.8	18.8	18.8
	Ozempic	11	34.4	34.4	53.1
	Trulicity	14	43.8	43.8	96.9
	Victoza	1	3.1	3.1	100.0
	Total	32	100.0	100.0	

DPP-4i

		Frequency	Percent
Missing	System	32	100.0

Combinations

		Frequency	Percent
Missing	System	32	100.0

patient gender

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	female	22	68.8	68.8	68.8
	male	10	31.3	31.3	100.0
	Total	32	100.0	100.0	

patient insurance type

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Commercial without Rx	1	3.1	3.1	3.1
	Medicare part D	31	96.9	96.9	100.0
	Total	32	100.0	100.0	

metformin use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	14	43.8	43.8	43.8
	Yes - both	17	53.1	53.1	96.9
	Yes-baseline only	1	3.1	3.1	100.0
	Total	32	100.0	100.0	

sulfonylurea use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	21	65.6	65.6	65.6
	Yes both baseline and 12 months	8	25.0	25.0	90.6
	Yes- baseline only	3	9.4	9.4	100.0
	Total	32	100.0	100.0	

meglitinide use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	32	100.0	100.0	100.0

TZD use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	32	100.0	100.0	100.0

other insulin use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	8	25.0	25.0	25.0
	Yes - 12 month only	1	3.1	3.1	28.1
	Yes baseline and 12 months	11	34.4	34.4	62.5
	Yes- baseline only	12	37.5	37.5	100.0
	Total	32	100.0	100.0	

T-Test

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	total # meds prior to PAP	12.06	32	3.741	.661
	total # meds 6 months after PAP	13.50	32	4.288	.758
Pair 2	total # DM meds prior to PAP	1.84	32	.767	.136
	total # DM meds 6 months after PAP	2.59	32	.756	.134
Pair 3	baseline A/C ratio	320.863	27	1126.1140	216.7207
	12 month A/C ratio	328.641	27	906.1218	174.3832
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1)	1.00	32	.508	.090
	# renal protective meds 12 months	1.97	32	.595	.105
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1)	1.28	32	.581	.103
	# CV protective meds 12 months	2.22	32	.659	.117
Pair 6	# hypoglycemia potential meds baseline	1.19	32	.644	.114
	# hypoglycemia potential meds 12 months	.94	32	.759	.134

Paired Samples Correlations

		N	Correlation	Significance	
				One-Sided p	Two-Sided p
Pair 1	total # meds prior to PAP & total # meds 6 months after PAP	32	.917	<.001	<.001
Pair 2	total # DM meds prior to PAP & total # DM meds 6 months after PAP	32	.555	<.001	<.001
Pair 3	baseline A/C ratio & 12 month A/C ratio	27	.970	<.001	<.001
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) & # renal protective meds 12 months	32	.854	<.001	<.001
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) & # CV protective meds 12 months	32	.761	<.001	<.001
Pair 6	# hypoglycemia potential meds baseline & # hypoglycemia potential meds 12 months	32	.684	<.001	<.001

Paired Samples Test

		Paired Differences			95% Confidence Interval of the ... Lower
		Mean	Std. Deviation	Std. Error Mean	
Pair 1	total # meds prior to PAP - total # meds 6 months after PAP	-1.437	1.722	.304	-2.058
Pair 2	total # DM meds prior to PAP - total # DM meds 6 months after PAP	-.750	.718	.127	-1.009
Pair 3	baseline A/C ratio - 12 month A/C ratio	-7.7778	330.6786	63.6391	-138.5899
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) - # renal protective meds 12 months	-.969	.309	.055	-1.080
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) - # CV protective meds 12 months	-.937	.435	.077	-1.094

Paired Samples Test

		Paired ... 95% Confidence Interval of the ... Upper	t	df	Significance One-Sided p Two-Sided p	
Pair 1	total # meds prior to PAP - total # meds 6 months after PAP	-.817	-4.724	31	<.001	<.001
Pair 2	total # DM meds prior to PAP - total # DM meds 6 months after PAP	-.491	-5.906	31	<.001	<.001
Pair 3	baseline A/C ratio - 12 month A/C ratio	123.0343	-.122	26	.452	.904
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) - # renal protective meds 12 months	-.857	-17.708	31	<.001	<.001
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) - # CV protective meds 12 months	-.781	-12.182	31	<.001	<.001

Paired Samples Test

		Paired Differences			95% Confidence Interval of the ... Lower
		Mean	Std. Deviation	Std. Error Mean	
Pair 6	# hypoglycemia potential meds baseline - # hypoglycemia potential meds 12 months	.250	.568	.100	.045

Paired Samples Test

		Paired ... 95% Confidence Interval of the ... Upper	t	df	Significance One-Sided p Two-Sided p	
Pair 6	# hypoglycemia potential meds baseline - # hypoglycemia potential meds 12 months	.455	2.490	31	.009	.018

Paired Samples Effect Sizes

			Standardizer ^a	Point Estimate	95% ... Lower
Pair 1	total # meds prior to PAP - total # meds 6 months after PAP	Cohen's d	1.722	-.835	-1.234
		Hedges' correction	1.765	-.815	-1.203
Pair 2	total # DM meds prior to PAP - total # DM meds 6 months after PAP	Cohen's d	.718	-1.044	-1.471
		Hedges' correction	.736	-1.018	-1.435
Pair 3	baseline A/C ratio - 12 month A/C ratio	Cohen's d	330.6786	-.024	-.401
		Hedges' correction	340.6156	-.023	-.389
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) - # renal protective meds 12 months	Cohen's d	.309	-3.130	-3.975
		Hedges' correction	.317	-3.054	-3.878
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) - # CV protective meds 12 months	Cohen's d	.435	-2.154	-2.784
		Hedges' correction	.446	-2.101	-2.716
Pair 6	# hypoglycemia potential meds baseline - # hypoglycemia potential meds 12 months	Cohen's d	.568	.440	.074
		Hedges' correction	.582	.429	.072

Paired Samples Effect Sizes

			95% ... Upper
Pair 1	total # meds prior to PAP - total # meds 6 months after PAP	Cohen's d	-.426
		Hedges' correction	-.416
Pair 2	total # DM meds prior to PAP - total # DM meds 6 months after PAP	Cohen's d	-.606
		Hedges' correction	-.591
Pair 3	baseline A/C ratio - 12 month A/C ratio	Cohen's d	.354
		Hedges' correction	.344
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) - # renal protective meds 12 months	Cohen's d	-2.276
		Hedges' correction	-2.221
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) - # CV protective meds 12 months	Cohen's d	-1.512
		Hedges' correction	-1.475
Pair 6	# hypoglycemia potential meds baseline - # hypoglycemia potential meds 12 months	Cohen's d	.800
		Hedges' correction	.781

- a. The denominator used in estimating the effect sizes.
Cohen's d uses the sample standard deviation of the mean difference.
Hedges' correction uses the sample standard deviation of the mean difference, plus a correction factor.

Bayesian One-way Repeated Measures ANOVA

Case Processing Summary

	N	Percent
Included	27	84.4%
Excluded	5	15.6%
Total	32	100.0%

Descriptive Statistics of Within-Subject Factor Levels

Dependent Variables	Mean	Std. Deviation	N	Min	Max
baseline A1c	8.867	1.8872	27	6.0	14.1
6 month A1c	7.063	.9552	27	5.7	9.5
12 month A1c	7.359	.9357	27	5.9	8.9

Bayesian Estimates of Group Means^a

Dependent Variables	Mode	Posterior		95% Credible Interval	
		Mean	Variance	Lower Bound	Upper Bound
baseline A1c	8.867	8.867	.064	8.372	9.361
6 month A1c	7.063	7.063	.064	6.569	7.557
12 month A1c	7.359	7.359	.064	6.865	7.854

a. Posterior distribution was estimated based on the Bayesian Central Limit Theorem.

Bayesian One-way Repeated Measures ANOVA

Case Processing Summary

	N	Percent
Included	29	90.6%
Excluded	3	9.4%
Total	32	100.0%

Descriptive Statistics of Within-Subject Factor Levels

Dependent Variables	Mean	Std. Deviation	N	Min	Max
baseline weight (kg)	99.748	19.0189	29	64.5	140.6
6 month weight	96.252	19.2417	29	61.8	143.5
12 month weight	95.648	19.4278	29	59.9	142.4

Bayesian Estimates of Group Means^a

Dependent Variables	Mode	Posterior		95% Credible Interval	
		Mean	Variance	Lower Bound	Upper Bound
baseline weight (kg)	99.748	99.748	12.312	92.871	106.626
6 month weight	96.252	96.252	12.312	89.374	103.129
12 month weight	95.648	95.648	12.312	88.771	102.526

a. Posterior distribution was estimated based on the Bayesian Central Limit Theorem.

Descriptives

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
# of patient assistance medications	32	1	4	1.91	.893
patient age	32	47	81	68.37	8.654
Valid N (listwise)	32				

